M15-563: Phase 2 extension of Study M15-562 to assess the long-term safety, tolerability, and efficacy of ABBV-8E12 in subjects with progressive supranuclear palsy (PSP)

Grants and Contracts Details

StatusFinished
Effective start/end date3/9/18 → 6/12/20

Funding

  • AbbVie Incorporated: $254,030.00